Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Date:11/7/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 7, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced third quarter 2013 financial results and will address frequently asked questions from investors during the quarterly conference call.  Questions, including recent inquiries regarding the clinical development program and prostate cancer market landscape, were submitted via the Company's website and other communication channels.  

The Company will discuss timelines for the primary registration Phase 3 SYNERGY trial, designed to evaluate a survival benefit for custirsen in combination with first-line docetaxel chemotherapy in men with metastatic castrate-resistant prostate cancer (CRPC). 

The planned efficacy interim analysis for SYNERGY has not yet occurred.  Once the interim analysis has been conducted and the Independent Data Monitoring Committee (IDMC) has rendered their recommendation, an update will be provided.  Final SYNERGY results continue to be expected by mid-2014; however, results could be announced sooner in the event the IDMC recommends an early unblinding of the trial.

"We are pleased with the tremendous clinical development progress of both custirsen and apatorsen in 2013,  and are excited about the future as we approach key data announcements for both of these product candidates," stated Scott Cormack, President and CEO of OncoGenex.  "We continue to execute according to plan and remain confident in our ability to change the lives of people living with cancer."

Third Quarter 2013 Financial Update and Results

  • Revenue for the three and nine months ended September 30, 2013 increased to $9.9 million and $21.3 million, respectively.  This compares to $6.6 million and $10.3
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
    3. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
    4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    7. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    8. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... Terascala, the industry leader in HPC management ... vice president of product management for Flexera Software, has ... Terascala’s software when combined with leading compute and storage ... and most reliable solutions for processing big data. , ... and broaden its product portfolio. His leadership in startups ...
    (Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
    (Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
    (Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
    Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
    ... Powell, former,President and Chief Operating Officer of SurModics ... Corporation., Under Powell,s guidance, SurModics developed medical ... commercialize products.,Powell joined SurModics in 1987 as the ... company,s transition from a diagnostics kit,manufacturer to a ...
    ... July 29 SCOLR Pharma, Inc.,(Amex: DDD ) ... on Thursday, August 7, 2008, at 8:30 a.m. Eastern. ... host a conference call at 11:30,a.m. Eastern, to discuss ... participate in the,conference call by dialing +1 888 680 ...
    ... VOLC ), a leading manufacturer and developer ... Coherence,Tomography (OCT) products designed to enhance the diagnosis ... announced that it will,report its operating results for ... 2008 on Tuesday, August 5., The company ...
    Cached Biology Technology:James C. Powell Joins Nerites Board of Directors 2SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern 2Volcano Corporation Schedules Second Quarter Conference Call, Webcast 2
    (Date:7/11/2014)... Mineral Research awarded Michael F. Holick, PhD, MD, of ... Louis V. Avioli Award. Holick, a professor of medicine, ... revolutionizing the understanding of vitamin D and its role ... member of the American Society for Bone and Mineral ... basic research. It is named for ASBMR,s first president ...
    (Date:7/11/2014)... 10, 2014---A team of researchers from The Chinese University ... a gene of wild soybean linked to salt tolerance, ... in saline soil. This study published online in ... novel genomic information for crop improvement. , Soybean is ... and human selection, cultivated soybeans have less genetic diversities ...
    (Date:7/11/2014)... July 11, 2014 Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
    Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
    ... known as a keystone species, filling such an important ... can collapse. Scientists are finding, however, that sea otters ... communities and alter the behavior of another top predator: ... towering kelp can reach heights of 250 feet and ...
    ... To help improve the success of oyster restoration efforts ... Environmental Science researcher Dr. Elizabeth North is leading a ... determine when oysters spawn and where their larvae go ... by a $750,000 competitive grant from the National Science ...
    ... DNA testing for hereditary breast cancer are associated with ... predictor of whether women had been able to leave ... the October issue of Genetics in Medicine , ... (ACMG). The journal is published by Lippincott Williams ...
    Cached Biology News:Decline in Alaskan sea otters affects bald eagles' diet 2Decline in Alaskan sea otters affects bald eagles' diet 3Study looks at psychological impact of gene test for breast cancer 2Study looks at psychological impact of gene test for breast cancer 3
    Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
    ... Stain for Mass Spectrometry Applications ,In ... (MS) has emerged as a powerful protein ... 2-D gels is now an important intermediate ... leads ultimately to identification of specific proteins ...
    ... M-PER Mammalian Protein Extraction Reagent ... lysis solution that means no ... no sonication! With M-PER Reagent, ... five minutes at room temperature, ...
    ... Optimization Kits with ammonium sulfate are compatible ... such as Tfl, Tth, and Pfu DNA ... of PCR systems in one experiment by ... primers into the PreMixes supplied with the ...
    Biology Products: